Tag: AstraZeneca

Brilinta fails to demonstrate benefit over clopidogrel for peripheral artery disease...

AstraZeneca has announced that top-line results from the EUCLID trial indicate that Brilinta (ticagrelor) did not demonstrate a benefit over clopidogrel in a symptomatic...

EUCLID trial to analyse monotherapy of ticagrelor versus clopidogrel in patients...

Despite “overwhelming data” demonstrating the efficacy of antiplatelet therapy in heart disease and stroke, data for antiplatelet therapy for peripheral arterial disease (PAD) are...